JenaValve Technology, Inc. announced that it has collected US$62.5 million in its Series C venture capital round. JenaValve Technology, Inc. is a privately-held, venture-backed producer of medical implants. The firm develops, manufactures, and markets transcatheter aortic valve implantation (TAVI) systems which is used for the treatment and maintenance of aortic valve disease.
The firm's latest financing round was led by Gimv. Belgium-based Gimv is a publicly traded investment firm and has no less than 30 years of experience in venture capital and private equity. Other investors included Legend Capital and Omega Funds. Omega Funds is an international healthcare focused investment firm. Legend Capital is the venture capital unit of Beijing-based Legend Holdings Ltd.
"JenaValve is gaining momentum in the European TAVI market with our novel transapical TAVI system primarily based on our products' unique features and clinical benefits. We are at an exciting point in our Company's growth as we commence a clinical study for our new transfemoral TAVI product and endeavor to significantly increase revenue in 2013, and beyond, from our transapical product across Europe and other global markets. Based on the positive feedback from our expanding network of hospital customers, we believe our technology represents an important advancement in the treatment of aortic valve disease," JenaValve Technology CEO, Helmut J. Straubiger, explained.
Join the Conversation